Vimseltinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 14 mg; 20 mg; 30 mg
Reference Brands: Romvimza
Category: Oncology Cancer Care
Vimseltinib is used in adults to treat giant cell tumor of the tendon sheath (also called tenosynovial giant cell tumor) that is not likely to improve with surgery. Before taking this medicine, tell your doctor if you have or have ever had an allergy to aspirin or food dye or liver disease. Vimseltinib can harm an unborn baby if the mother or the father is using vimseltinib. Vimseltinib is available in Capsules and strengths such as 14 mg; 20 mg; 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Vimseltinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Vimseltinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Vimseltinib, an investigational oncology drug, is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality according to GMP standards. In the US, regulatory review involves validation, safety assessments, and clinical trial data submission. In the EU, approval processes include validation, stability testing, and conformity with MDR standards. These dossiers encompass safety profiles, clinical trial results, and manufacturing practices
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Vimseltinib is used for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgical removal of the tumor would cause severe complications or functional disability. It works by blocking the CSF1R receptor, which helps reduce the growth and spread of tumor cells in the affected joints or tissues.
Vimseltinib is a small-molecule compound formulated as oral capsules. It contains the active ingredient vimseltinib, a selective colony-stimulating factor 1 receptor (CSF1R) inhibitor. The capsules also include inactive ingredients such as lactose monohydrate, crospovidone, and magnesium stearate.
The trade name of Vimseltinib is Romvimza.
Vimseltinib is developed and manufactured by Deciphera Pharmaceuticals, LLC, which is part of the Ono Pharmaceutical Group.
The generic name of the product is Vimseltinib.
The brand name of the product is Romvimza.
Vimseltinib (Romvimza) is manufactured by Deciphera Pharmaceuticals, LLC at its facility in Waltham, Massachusetts, USA.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
